NasdaqGM - Nasdaq Real Time Price USD

ARS Pharmaceuticals, Inc. (SPRY)

Compare

14.29

-0.03

(-0.21%)

At close: January 30 at 4:00:01 PM EST

14.22

-0.07

(-0.49%)

After hours: 7:26:33 PM EST

VR Resources Says Drilling Underway At Silverback Copper-Gold Project

VR Resources (VRR.V) on Tuesday said drilling is now underway at its Silverback copper-gold project

PREMIUM
MT Newswires 2 days ago

SPRY
-0.21%
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine nasal spray) 2 mg for undesignated use meets applicable state law requirements Interested schools can visit neffy.com/community-programs to apply SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that

GlobeNewswire 9 days ago

SPRY
-0.21%
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports.

Investor's Business Daily 17 days ago

AXSM

BBIO

HRMY
Exploring Three High Growth Tech Stocks In The United States

Over the last 7 days, the United States market has experienced a 2.1% drop, yet it remains up by 21% over the past year with earnings projected to grow by 15% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on evolving market trends.

Simply Wall St. 17 days ago

RIGL

SPRY
-0.21%
HCP
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and short-term investments of $314.0 million at year-end 2024 to support an operating runway of at least three years Company to present at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 7:30am PT SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patie

GlobeNewswire 17 days ago

SPRY
-0.21%
ARS Pharmaceuticals files for approval of neffy in Canada, U.K.

ARS Pharmaceuticals (SPRY) announced that ARS Pharma has filed for approval of neffy 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy, on behalf of its licensing partner, ALK- Abello A/S. neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. In November 2024, ARS Pharma announced a licensing agreement providing ALK with exclusive rights to commercia

TipRanks 23 days ago

SPRY
-0.21%
ARS Pharma seeks approval for epinephrine spray in Canada and UK

ARS Pharma has established licensing partnerships for the spray in China, Japan, Australia and New Zealand.

Medical Device Network 23 days ago

SPRY
-0.21%
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that ARS Pharma has filed for approval of n

GlobeNewswire 24 days ago

SPRY
-0.21%
Top US Growth Companies With Insider Ownership In January 2025

As 2025 begins, U.S. stock markets are showing signs of recovery following a challenging end to 2024, with major indices like the Dow Jones Industrial Average and S&P 500 poised for gains. In this context, growth companies with high insider ownership can be particularly appealing, as they often indicate strong confidence from those who know the business best and may offer resilience amid market fluctuations.

Simply Wall St. 28 days ago

ENFN

SPRY
-0.21%
AIRS
Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green

Key Insights Given the large stake in the stock by institutions, ARS Pharmaceuticals' stock price might be vulnerable...

Simply Wall St. last month

SPRY
-0.21%
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business o

GlobeNewswire last month

SPRY
-0.21%
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13-16, 2025 in San Francisco. Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma, will present on Wednesday, January 1

GlobeNewswire last month

SPRY
-0.21%
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agenciesSAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that its licensing partners in China, Japan and Australia have filed for approval of neffy®

GlobeNewswire last month

SPRY
-0.21%
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Qualifying public and private K-12 Schools in the U.S. will be eligible to receive two free cartons (four single use doses) of neffy® (epinephrine nasal spray) 2mg for use in emergency treatment of allergic reactions including anaphylaxis Interested schools are encouraged to review applicable state laws and regulations to ensure neffy for undesignated use meets all requirements SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedi

GlobeNewswire last month

SPRY
-0.21%
US Growth Stocks With High Insider Ownership For November 2024

As the U.S. market navigates a mixed landscape with the Dow Jones Industrial Average reaching record highs and investors closely monitoring inflation data, growth stocks continue to capture attention for their potential returns. In this environment, companies with high insider ownership can be particularly appealing, as they often signal confidence from those who know the business best.

Simply Wall St. 2 months ago

DQ

SPRY
-0.21%
AFYA
Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term

With the business potentially at an important milestone, we thought we'd take a closer look at ARS Pharmaceuticals...

Simply Wall St. 2 months ago

SPRY
-0.21%
ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...

Despite a net loss, ARS Pharmaceuticals Inc (SPRY) is optimistic about NEPHI's market potential and strategic global expansion.

GuruFocus.com 2 months ago

SPRY
-0.21%
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -11.11% and 8.50%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

SPRY
-0.21%
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royaltiesWell-capitalized with $349.6 million in cash, cash equivalen

GlobeNewswire 2 months ago

SPRY
-0.21%
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize neffy, the first and only needle-free emergency treatment for Type I allergic reactions including anaphylaxis, in Europe, Canada and other geographies outside of the U.S. ARS Pharma retains all rights to neffy in the U.S., and there are no changes to its existing partnerships in Japan, China, Australia and New Zealand. Published first on TheFly – the ultimat

TipRanks 2 months ago

AKBLF

SPRY
-0.21%

Performance Overview

Return	SPRY	S&P 500
YTD	+34.56%	+2.78%
1-Year	+120.52%	+23.20%
3-Year	+215.45%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ARS Pharmaceuticals, Inc. (SPRY)

VR Resources Says Drilling Underway At Silverback Copper-Gold Project

ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Exploring Three High Growth Tech Stocks In The United States

ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)

ARS Pharmaceuticals files for approval of neffy in Canada, U.K.

ARS Pharma seeks approval for epinephrine spray in Canada and UK

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Top US Growth Companies With Insider Ownership In January 2025

Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

US Growth Stocks With High Insider Ownership For November 2024

Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected To Breakeven In The Medium-Term

ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ...

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

Performance Overview